Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Proactively manage your pharmacy inventory
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
|Title:||Methods for treating acromegaly and giantism with growth hormone antagonists|
|Abstract:||The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants-have growth-inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to animals, or transgenic animals may be made that express the antagonist. Animals have been made which exhibited a reduced growth phenotype. The invention also describes methods of treating acromegaly, gigantism, cancer, diabetes, vascular eye diseases (diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, retinopathy of sickle-cell anemia, etc.) as well as nephropathy and other diseases, by administering an effective amount of a growth hormone antagonist. The invention also provides pharmaceutical formulations comprising one or more growth hormone antagonists.|
|Inventor(s):||Kopchick; John J. (Athens, OH), Chen; Wen Y. (Athens, OH)|
|Assignee:||Ohio University/Edison Biotechnology Institute (Athens, OH)|
Patent Claim Types:|
see list of patent claims
|Patent Number||Expiration Date|
|6,583,115||June 24, 2015|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.